Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference

Mar 23rd, 2022 8:00 EST

BOSTON and ATLANTA, March 23, 2022 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company’s President & Chief Executive Officer will present in the Maxim Group 2022 Virtual Growth Conference, being held from March 28th through 30th.

The presentation will be available for on-demand viewing starting at 9:00am ET on Monday, March 28, 2022, and may be accessed under “News & Events” in the Investors section of the Company’s website, www.inhibikase.com.

About Inhibikase (www.inhibikase.com)Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, or MSA, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company’s RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

Social Media DisclaimerInvestors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use TwitterFacebookLinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Contacts:

Company Contact:Milton H. Werner, PhDPresident & CEO678-392-3419[email protected]

Investor Relations:Alex LoboSternIR, Inc.[email protected]

SOURCE Inhibikase Therapeutics, Inc.

Link to Source

Leave a Comment

SOTD Membership

Register by Email

or
Already a member? Sign In